Premium
Ginsenoside Rd therapy improves histological and functional recovery in a rat model of inflammatory bowel disease
Author(s) -
Yang Ningning,
Liang Guoying,
Lin Jing,
Zhang Sijia,
Lin Qiuchi,
Ji Xuechun,
Chen Haoyuan,
Li Ning,
Jin Shizhu
Publication year - 2020
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6734
Subject(s) - endogeny , stem cell , ginseng , inflammatory bowel disease , pharmacology , subcutaneous injection , cell growth , ginsenoside , saline , medicine , endocrinology , chemistry , biology , pathology , disease , microbiology and biotechnology , biochemistry , alternative medicine
Ginsenoside Rd (GRd) is a biologically active component of ginseng that stimulates the proliferation of endogenous stem cells. The objective of our research was to evaluate the utility of GRd in gastrointestinal mucosal regeneration in a rat model of inflammatory bowel disease (IBD) and to clarify whether GRd exerts its pharmacological effects by modulating endogenous intestinal stem cells. The IBD rat model was established via subcutaneous injection of indomethacin, and 10, 20, or 40 mg/kg GRd or an equal volume of physiological saline was then administered orally to rats in different groups every day for seven consecutive days. We observed that GRd treatment, especially 20 mg/kg GRd, significantly reduced indomethacin‐induced damage compared with that in the control group. By measuring the mRNA and protein levels of the intestinal stem cell markers Bmi and Msi‐1 and the intestinal epithelial cell marker CDX‐2 as well as by double‐labelling these markers with 5‐bromo‐2‐deoxyuridine (BrdU), we inferred that GRd could stimulate the proliferation and differentiation of endogenous intestinal stem cells in IBD model rats, leading to improved recovery of intestinal function.